Alexion Pharmaceuticals (ALXN) stock had a bullish inflow of $48.16 million worth of trades on uptick and an outflow of $44.85 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.07. The net money flow into the stock was $3.31 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $6.56 million. An inflow of $4.51 million block trade was recorded on downticks. $11.07 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 2.45 in favor of the bulls. However, Alexion Pharmaceuticals (ALXN) stock traded down $2.22 , and reached $123.76, a drop of -1.76% over the previous day. On a weekly basis, the stock is -2.72%, over the previous weeks close.
Alexion Pharmaceuticals, Inc. has lost 5.06% in the last five trading days and dropped 3.3% in the last 4 weeks. Alexion Pharmaceuticals, Inc. is up 8.4% in the last 3-month period. Year-to-Date the stock performance stands at -35.12%.
Alexion Pharmaceuticals (ALXN) : 11 brokerage houses believe that Alexion Pharmaceuticals (ALXN) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Alexion Pharmaceuticals (ALXN). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 19 Wall Street Analysts endorse the stock as a Buy with a rating of 1.82.
Alexion Pharmaceuticals (NASDAQ:ALXN): stock was range-bound between the intraday low of $123.26 and the intraday high of $127.45 after having opened at $127.45 on Wednesdays session. The stock finally closed in the red at $127.45, a loss of -1.76%. The stock remained in the red for the whole trading day. The total traded volume was 1,384,063 shares. The stock failed to cross $127.45 in Wednesdays trading. The stocks closing price on Thursday was $125.98.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.